CGEM Cullinan Therapeutics, Inc.: institutional ownership and insider trading
193 funds reported holding $1.36B of Cullinan Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $112M, with 28 new positions and 19 funds selling out; over the last 12 months insiders bought $1.39M and sold $2.51M on the open market.
CGEM revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$53.7M
- Quarter ended Mar 31, 2026: revenue n/a, net income −$49.7M
- Quarter ended Dec 31, 2025: revenue n/a, net income −$50.7M
- Quarter ended Sep 30, 2025: revenue n/a, net income −$50.6M
Famous investors holding CGEM
- Renaissance Technologies (Renaissance Technologies): $5.95M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $9.35M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $6.67M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $4.96M, 0.0% of the portfolio
Largest institutional holders of CGEM
- MPM BioImpact LLC — $177M
- Lynx1 Capital Management LP — $163M
- BVF INC/IL — $105M
- BlackRock, Inc. (BLK) — $95.3M
- PRICE T ROWE ASSOCIATES INC /MD/ — $69.7M
- STATE STREET CORP (STT, STT-PG) — $66.8M
- Kynam Capital Management, LP — $56.7M
- VANGUARD CAPITAL MANAGEMENT LLC — $47.6M
- RTW INVESTMENTS, LP — $43.1M
- Siren, L.L.C. — $34.5M
Recent CGEM insider trades
- Sep 8, 2026: Michaelson Jennifer sold 8,000 shares ($173K)
- Aug 13, 2026: Michaelson Jennifer sold 30,000 shares ($608K)
- Jul 6, 2026: Michaelson Jennifer sold 8,000 shares ($143K)
- May 5, 2026: Michaelson Jennifer sold 8,000 shares ($117K)
5%+ owners
- BVF PARTNERS L P/IL: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- T. Rowe Price Associates, Inc.: 6.2% (Schedule 13G, filed Aug 14, 2026)
- STATE STREET CORPORATION: 6.0% (Schedule 13G, filed Aug 7, 2026)